TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35864545

Group type: EXPERIMENTAL
Intervention: Warning Labels (WL)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Nutrient Facts Panel (NF)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Traditional Warning Labels (WL)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Numeric Warning Labels (WL)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Warning Labels with cartoon characters (WL + C)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Video
Number of subjects: 408
Study: 33991134

Group type: EXPERIMENTAL
Intervention: CO2 exposure at 1450 ppm (decreased ventilation)
Number of subjects: 15

Group type: COMPARATOR
Intervention: CO2 exposure at 900 ppm (reference)
Number of subjects: 15

Group type: COMPARATOR
Intervention: CO2 exposure at 1450 ppm (reference condition with added pure CO2)
Number of subjects: 15
Study: 33003524

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No calibration Dexcom G6 CGM
Number of subjects: 24
Study: 35340223

Group type: EXPERIMENTAL
Intervention: Mosapride citrate tablets combined with ShenQu Xiaoshi oral liquid
Number of subjects: 136

Group type: COMPARATOR
Intervention: Western medicine group (Mosapride citrate tablets)
Number of subjects: 136
Study: 33153827

Group type: EXPERIMENTAL
Intervention: Ultra-processed foods (NOVA-4 foods) consumption in patients with AN
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Ultra-processed foods (NOVA-4 foods) consumption in patients with BN
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Ultra-processed foods (NOVA-4 foods) consumption in patients with BED
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Binge eating episodes
Number of subjects: 73
Study: 32931496

Group type: EXPERIMENTAL
Intervention: Biannual azithromycin distribution
Number of subjects: 27222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27222
Study: 34767705

Group type: EXPERIMENTAL
Intervention: Mitral-valve surgery plus tricuspid annuloplasty (TA)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Mitral-valve surgery alone
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Mitral-valve surgery plus TA
Number of subjects: 401
Study: 34159294

Group type: EXPERIMENTAL
Intervention: 3 months adjuvant chemotherapy
Number of subjects: 160

Group type: COMPARATOR
Intervention: 6 months adjuvant chemotherapy
Number of subjects: 160
Study: 32238273

Group type: EXPERIMENTAL
Intervention: SYNTAX Score II (SS-II) ≤ 23
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: SYNTAX Score II (23 < SS-II ≤ 31)
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: SYNTAX Score II (SS-II > 31)
Number of subjects: 723
Study: 36183748

Group type: EXPERIMENTAL
Intervention: Edwards Magna bioprosthesis
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: St.Jude Epic bioprosthesis
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Sorin Mitroflow bioprosthesis
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (Magna)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (Epic)
Number of subjects: 300
Study: 33516531

Group type: EXPERIMENTAL
Intervention: Active surveillance
Number of subjects: 1638

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 1638
Study: 32159870

Group type: COMPARATOR
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 959

Group type: COMPARATOR
Intervention: Local anaesthesia (LA)
Number of subjects: 959

Group type: COMPARATOR
Intervention: Dry needling therapy
Number of subjects: 959

Group type: COMPARATOR
Intervention: Dry needling
Number of subjects: 959

Group type: COMPARATOR
Intervention: Botulinum toxin-A (BTX-A)
Number of subjects: 959

Group type: COMPARATOR
Intervention: Granisetron
Number of subjects: 959

Group type: COMPARATOR
Intervention: PRP
Number of subjects: 959
Study: 35220641

Group type: EXPERIMENTAL
Intervention: MflCas 2% topical treatment after 56 days
Number of subjects: 0
Study: 32720415

Group type: EXPERIMENTAL
Intervention: Indigenous food (IF) consumption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Food Accessed Diversity Index (FADI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minimum dietary diversity score for women (MDD-W)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutritional status assessment
Number of subjects: 0
Study: 36067012

Group type: EXPERIMENTAL
Intervention: Skin tests (STs) retest after initial evaluation (IE)
Number of subjects: 545
Study: 33529256

Group type: EXPERIMENTAL
Intervention: Group antenatal care
Number of subjects: 8843

Group type: COMPARATOR
Intervention: Individual antenatal care (control)
Number of subjects: 8843

Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 8843

Group type: EXPERIMENTAL
Intervention: Intervention sites
Number of subjects: 8843
Study: 32489274

Group type: EXPERIMENTAL
Intervention: ibrutinib–rituximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: acalabrutinib–obinutuzumab or acalabrutinib monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: zanubrutinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: venetoclax–obinutuzumab
Number of subjects: 0
Study: 35762237

Group type: EXPERIMENTAL
Intervention: CO2 exposure at 4000 ppm (Moderately High: MH)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CO2 exposure at 40,000 ppm (High: H)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal CO2 condition (C)
Number of subjects: 12
Study: 34205461

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 28
Study: 36423412

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioural therapy (ICBT)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Internet-delivered supportive therapy (ISUPPORT)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: ICBT
Number of subjects: 103
Study: 32037021

Group type: EXPERIMENTAL
Intervention: Intensive intervention (12 sessions lasting 2 hours each, 3 follow-up monthly sessions, and 1 closing session)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Nonintensive control (3 sessions about healthy lifestyles lasting 1 hour each)
Number of subjects: 171
Study: 35672921

Group type: EXPERIMENTAL
Intervention: One Drop digital health program
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 125
Study: 32627049

Group type: EXPERIMENTAL
Intervention: Corticomedullary contrast-enhanced CT (CM-CECT)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Nephrographic contrast-enhanced CT (NG-CECT)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Combined data across all three phases
Number of subjects: 177

Group type: COMPARATOR
Intervention: Machine learning models trained with one phase
Number of subjects: 177
Study: 36308296

Group type: EXPERIMENTAL
Intervention: Cemiplimab 350 mg every 3 weeks
Number of subjects: 563

Group type: COMPARATOR
Intervention: Platinum-doublet chemotherapy
Number of subjects: 563
Study: 33933474

Group type: COMPARATOR
Intervention: BEAM (carmustine, etoposide, cytarabine, melphalan)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Mx-Mel (mitoxantrone, melphalan)
Number of subjects: 101
Study: 35948209

Group type: EXPERIMENTAL
Intervention: Monthly treatment with pegcetacoplan
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Every-other-month (EOM) treatment with pegcetacoplan
Number of subjects: 156

Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 156
Study: 33974324

Group type: EXPERIMENTAL
Intervention: Egg intervention (1 egg per day)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Control group (usual diet)
Number of subjects: 660
Study: 36239660

Group type: EXPERIMENTAL
Intervention: Total Intravenous Anesthesia (TIVA)
Number of subjects: 111
Study: 33721598

Group type: EXPERIMENTAL
Intervention: Pitolisant
Number of subjects: 118
Study: 32316854

Group type: EXPERIMENTAL
Intervention: Dynamic potentiating (DYN)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 40
Study: 36435822

Group type: EXPERIMENTAL
Intervention: Laser correction technology
Number of subjects: 71

Group type: COMPARATOR
Intervention: Traditional correction method
Number of subjects: 71
Study: 33750594

Group type: EXPERIMENTAL
Intervention: Virtual counselor (VICKY)
Number of subjects: 273

Group type: COMPARATOR
Intervention: My Family Health Portrait (MFHP)
Number of subjects: 273
Study: 33078673

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy screening
Number of subjects: 0
Study: 34459496

Group type: EXPERIMENTAL
Intervention: Walking training combined with respiratory muscle training (W+RMT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Respiratory muscle training (RMT)
Number of subjects: 30
Study: 33610562

Group type: EXPERIMENTAL
Intervention: Vitamin C (1 gram)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 34308854

Group type: EXPERIMENTAL
Intervention: RA combined with CB
Number of subjects: 120

Group type: COMPARATOR
Intervention: Semicompliant balloon (SB)
Number of subjects: 120
Study: 32013958

Group type: EXPERIMENTAL
Intervention: Dapoxetine treatment for 4 weeks
Number of subjects: 154
Study: 35224797

Group type: EXPERIMENTAL
Intervention: HYP (4300 m)
Number of subjects: 9

Group type: COMPARATOR
Intervention: NORM (1585 m)
Number of subjects: 9
Study: 34959923

Group type: EXPERIMENTAL
Intervention: AP collagen peptides (APCPs) 1000 mg
Number of subjects: 50
Study: 35152416

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Nortriptyline (1-year follow-up)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (1-year follow-up)
Number of subjects: 47
Study: 33616185

Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) home intervention
Number of subjects: 223

Group type: COMPARATOR
Intervention: Certified asthma educator (AE-C) services
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Both interventions (CHW and AE-C)
Number of subjects: 223
Study: 32380427

Group type: EXPERIMENTAL
Intervention: Early relapse (ER) group
Number of subjects: 163

Group type: COMPARATOR
Intervention: Progressive disease (PD) group
Number of subjects: 163
Study: 35167133

Group type: EXPERIMENTAL
Intervention: Urea-glycerol cream (UGC)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Glycerol cream (GC)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Paraffin cream (PC)
Number of subjects: 49

Group type: COMPARATOR
Intervention: No-treatment control (NTC)
Number of subjects: 49
Study: 34271702

Group type: EXPERIMENTAL
Intervention: Majority rule dynamics with ε≥ε_{c}=1/9
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Majority rule dynamics with ε<ε_{c}
Number of subjects: 0
Study: 32330237

Group type: EXPERIMENTAL
Intervention: Breast milk (BF)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Soy-based formula (SF)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dairy-based milk formula (MF)
Number of subjects: 16
Study: 35490196

Group type: EXPERIMENTAL
Intervention: UCMV (umbilical cord milking with ventilation)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: DCCV (delayed cord clamping with ventilation)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: UCM (umbilical cord milking without ventilation)
Number of subjects: 23
Study: 32092479

Group type: EXPERIMENTAL
Intervention: Denosumab therapy for 10 years
Number of subjects: 0
Study: 33887775

Group type: EXPERIMENTAL
Intervention: Buffalo Concussion Treadmill Test (BCTT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cycling test of exertion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both tests
Number of subjects: 20
Study: 35443784

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) 50 mg b.i.d.
Number of subjects: 12
Study: 34491650

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (at Xin (CO15), Gan (CO12), Shenmen (TF4), Pizhixia (AT4), Neifenmi (CO18)), once every 3 days for 4 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional dosage reduction method (sertraline hydrochloride reduced by 25% every week)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional dosage reduction method
Number of subjects: 72
Study: 33414090

Group type: EXPERIMENTAL
Intervention: Pharmacy-based diabetes screening interventions
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: High-performing pharmacists
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Low-performing pharmacists
Number of subjects: 339
Study: 32105971

Group type: EXPERIMENTAL
Intervention: Patient infotainment system (study group)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 86
Study: 33009351

Group type: EXPERIMENTAL
Intervention: 10% velocity decrease (G10)
Number of subjects: 17

Group type: COMPARATOR
Intervention: 20% velocity decrease (G20)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Training intervention
Number of subjects: 17
Study: 33421964

Group type: EXPERIMENTAL
Intervention: Cycling Exercise Training (CET) combined with General Rehabilitation (GR) for 12 weeks, n = 20
Number of subjects: 40

Group type: COMPARATOR
Intervention: General Rehabilitation (GR) alone for 12 weeks, n = 20
Number of subjects: 40
Study: 37179020

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 513

Group type: COMPARATOR
Intervention: Trastuzumab emtansine (T-DM1)
Number of subjects: 513
Study: 34390083

Group type: EXPERIMENTAL
Intervention: Tetracycline-levofloxacin (TL) quadruple therapy (tetracycline 500 mg QID, levofloxacin 500 mg QD, esomeprazole 40 mg BID, tripotassium dicitrato bismuthate 300 mg QID)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Amoxicillin-levofloxacin (AL) quadruple therapy (amoxicillin 500 mg QID, levofloxacin 500 mg QD, esomeprazole 40 mg BID, tripotassium dicitrato bismuthate 300 mg QID)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Tetracycline-levofloxacin (TL) quadruple therapy
Number of subjects: 108

Group type: COMPARATOR
Intervention: Amoxicillin-levofloxacin (AL) quadruple therapy
Number of subjects: 108
Study: 32567223

Group type: EXPERIMENTAL
Intervention: AE/CMA+ group
Number of subjects: 161

Group type: COMPARATOR
Intervention: AE/CMA− group
Number of subjects: 161

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 161
Study: 35314457

Group type: EXPERIMENTAL
Intervention: Longitudinal changes in TNFR1 slope in AASK
Number of subjects: 1172

Group type: EXPERIMENTAL
Intervention: Longitudinal changes in TNFR2 slope in AASK
Number of subjects: 1172

Group type: EXPERIMENTAL
Intervention: Longitudinal changes in TNFR1 in VA NEPHRON-D
Number of subjects: 1172

Group type: EXPERIMENTAL
Intervention: Longitudinal changes in TNFR2 in VA NEPHRON-D
Number of subjects: 1172
Study: 33393112

Group type: EXPERIMENTAL
Intervention: Lanreotide depot/autogel 120 mg every 4 weeks (LAN)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 32422066

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 278

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 278
Study: 34104096

Group type: EXPERIMENTAL
Intervention: Planox® lemon verbena extract (LVE) 400 mg/human/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (0 mg/human/day)
Number of subjects: 60
Study: 36178686

Group type: EXPERIMENTAL
Intervention: Patient with diabetes
Number of subjects: 383

Group type: COMPARATOR
Intervention: Patient with opioid use disorder
Number of subjects: 383

Group type: COMPARATOR
Intervention: Physicians with more than 20 years in practice (for opioid use disorder)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Physicians with more than 20 years in practice (for diabetes)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Women physicians (for opioid use disorder)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Women physicians (for diabetes)
Number of subjects: 383
Study: 33789735

Group type: EXPERIMENTAL
Intervention: Daily disposable multifocal contact lenses with + 0.50D addition
Number of subjects: 100

Group type: COMPARATOR
Intervention: Daily disposable soft contact lenses (SCLs)
Number of subjects: 100
Study: 32756488

Group type: EXPERIMENTAL
Intervention: Shaded white leaf tea (SWLT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo green tea
Number of subjects: 0
Study: 36104613

Group type: EXPERIMENTAL
Intervention: DFV890 + standard-of-care (SoC)
Number of subjects: 143

Group type: COMPARATOR
Intervention: SoC alone
Number of subjects: 143
Study: 33540464

Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index (CCI) in patients with AECOPD
Number of subjects: 44

Group type: COMPARATOR
Intervention: Charlson Comorbidity Index (CCI) in patients without AECOPD
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Optimal cut-off point for CCI
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Optimal cut-off point for CIRS
Number of subjects: 44
Study: 34821020

Group type: EXPERIMENTAL
Intervention: Hetrombopag (2.5, 3.75, 5, or 7.5 mg once daily) during Stage 4
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Hetrombopag during Stage 3
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Adverse events in the hetrombopag group
Number of subjects: 339
Study: 34684151

Group type: EXPERIMENTAL
Intervention: Target-Controlled Infusion (TCI)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Manual Infusion (MI)
Number of subjects: 31
Study: 32912260

Group type: EXPERIMENTAL
Intervention: Family-based intervention (rewards to child contingent on both child's and parent's physical activity)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Child-based intervention (rewards to child contingent on child's physical activity)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Family-based intervention
Number of subjects: 316

Group type: COMPARATOR
Intervention: Child-based intervention
Number of subjects: 316
Study: 35177277

Group type: EXPERIMENTAL
Intervention: Olaparib (OLA) monotherapy (300 mg tablets, BID)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Physician's choice chemotherapy (CT)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Olaparib (OLA) monotherapy
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Olaparib (OLA) monotherapy in PSOC
Number of subjects: 160

Group type: COMPARATOR
Intervention: Physician's choice chemotherapy (CT) in PSOC
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Olaparib (OLA) monotherapy in PROC
Number of subjects: 160

Group type: COMPARATOR
Intervention: Physician's choice chemotherapy (CT) in PROC
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Olaparib (OLA) monotherapy in heavily pretreated PROC (>4 prior lines)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Physician's choice chemotherapy (CT) in heavily pretreated PROC (>4 prior lines)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Olaparib (OLA) monotherapy in BRCA-mutated PROC
Number of subjects: 160

Group type: COMPARATOR
Intervention: Physician's choice chemotherapy (CT) in BRCA-wildtype PROC
Number of subjects: 160
Study: 32768376

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Combined Training (AT+RT)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Control (lectures about health promotion)
Number of subjects: 415
Study: 33832406

Group type: EXPERIMENTAL
Intervention: Aripiprazole at a dose of up to 20 mg daily
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Quetiapine at a dose of up to 600 mg daily
Number of subjects: 90

Group type: COMPARATOR
Intervention: Haloperidol at a dose of up to 30 mg daily
Number of subjects: 90
Study: 32074243

Group type: EXPERIMENTAL
Intervention: Neurohormonal antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization and mitral valve repair
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transcatheter mitral valve repair
Number of subjects: 0
Study: 34331536

Group type: EXPERIMENTAL
Intervention: Statin use (prevalent users)
Number of subjects: 5580

Group type: COMPARATOR
Intervention: Statin initiators (new users)
Number of subjects: 5580
Study: 34324783

Group type: EXPERIMENTAL
Intervention: Corticosteroids administered to PWH (33.3%)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: HIV-positive patients (PWH)
Number of subjects: 126

Group type: COMPARATOR
Intervention: HIV-negative patients (non-PWH)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Overall comparison of mortality
Number of subjects: 126
Study: 32977459

Group type: EXPERIMENTAL
Intervention: Tele-CBT
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard bariatric post-operative care
Number of subjects: 100
Study: 35271566

Group type: EXPERIMENTAL
Intervention: Role uncertainty
Number of subjects: 0

Group type: COMPARATOR
Intervention: State empathy induction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trait empathy (affective empathy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Role awareness
Number of subjects: 0
Study: 36253804

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 33645135

Group type: EXPERIMENTAL
Intervention: Shenxiong Injection combined with conventional treatment
Number of subjects: 6197

Group type: EXPERIMENTAL
Intervention: Honghua Injection combined with conventional treatment
Number of subjects: 6197

Group type: EXPERIMENTAL
Intervention: Shuxuetong Injection combined with conventional treatment
Number of subjects: 6197

Group type: EXPERIMENTAL
Intervention: Shenkang Injection combined with conventional treatment
Number of subjects: 6197
Study: 35077558

Group type: EXPERIMENTAL
Intervention: Simple Gamification Group (SGG)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Technology-Based Gamification Group (TGG)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 70
Study: 33627275

Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - 9 sessions of intervallic exposure to heat (100 ± 2 °C) over 3 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control Group (CG) - No specific intervention mentioned
Number of subjects: 40
Study: 32567996

Group type: EXPERIMENTAL
Intervention: Continuous verbal rehabilitation training under inclusive education
Number of subjects: 60

Group type: COMPARATOR
Intervention: No continuous verbal rehabilitation training
Number of subjects: 60